|Gut microbiota metabolite protects against obesity: study
Vanderbilt researchers have discovered that beneficial bacteria in the small intestines produce a compound that protects against obesity.
Friday, December 8th, 2023
|Tumor antigens key to improving cancer immunotherapy study
Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.
Friday, November 17th, 2023
|Crowe Osheroff honored by AAMC
Vanderbilts James E. Crowe Jr MD and Neil Osheroff PhD are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event.
Monday, October 30th, 2023
|Study finds hallmarks of T cell exhaustion within hours of tumor exposure
Vanderbilt researchers found that T cells become exhausted within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.
Wednesday, August 23rd, 2023
|Study reveals new strategy for reducing tumor growth, metastasis
A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
Thursday, December 17th, 2020
|V Scholar Award to support Byndloss’ cancer research
Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has received a V Scholar Award from the V Foundation for Cancer Research.
Wednesday, November 18th, 2020
|New therapeutic target for lung cancer
Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.
Thursday, November 12th, 2020
|Richmond receives legacy award from Society for Leukocyte Biology
Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.
Friday, December 13th, 2019
|Project seeks new way to assess immunotherapy effectiveness
GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.
Thursday, November 7th, 2019
|Rathmell lands award from Lupus Research Alliance
Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.
Thursday, October 31st, 2019
|Pietenpol, Wilson land Komen cancer research support
Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.
Thursday, October 24th, 2019
|Potential second-line melanoma treatment identified
A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Friday, August 30th, 2019
|New window on fibrosis
A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.
Friday, August 9th, 2019
|Center for Immunobiology grows, bolsters program
The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.
Friday, July 19th, 2019
|Gore, King elected to 2019 IAMBE Class of Fellows
John Gore, PhD, director of the Vanderbilt University Institute of Imaging Science (VUIIS), and Michael King, PhD, J. Lawrence Wilson Professor and chair of the Department of Biomedical Engineering at Vanderbilt University, were recently elected to the International Academy of Medical and Biological Engineering (IAMBE) 2019 Class of Fellows in recognition of their contributions in the field of medical and biological engineering.
Thursday, May 30th, 2019
|RNA processing and antiviral immunity
A recent study in Nature Communications defines the in vivo substrates of RIG-I like receptors (RLRs) during an oncogenic virus infection and reveals a relationship between cellular RNA processing and an innate antiviral immune response.
Friday, December 14th, 2018
|VICC investigators in spotlight at AACR conference
A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Carlos L. Arteaga, M.
Thursday, May 19th, 2016